Effects of ezetimibe, a new cholesterol absorption inhibitor, on plasma lipids in patients with primary hypercholesterolemia.
about
Regulatory challenges for new drugs to treat obesity and comorbid metabolic disordersTreatment of dyslipidemia with lovastatin and ezetimibe in an adolescent with cholesterol ester storage disease.Optimizing Treatment of Familial Hypercholesterolemia in Children and AdolescentsFamilial hypercholesterolemia: present and future managementFenofibrate: a novel formulation (Triglide) in the treatment of lipid disorders: a reviewThe target of ezetimibe is Niemann-Pick C1-Like 1 (NPC1L1)Comparison of the efficacy of administering a combination of ezetimibe plus fenofibrate versus atorvastatin monotherapy in the treatment of dyslipidemia.Opposing Gatekeepers of Apical Sterol Transport: Niemann-Pick C1-Like 1 (NPC1L1) and ATP-Binding Cassette Transporters G5 and G8 (ABCG5/ABCG8)Cholesterol and benign prostate disease.Hypercholesterolemia induces angiogenesis and accelerates growth of breast tumors in vivo.Influence of previous statin therapy on cholesterol-lowering effect of ezetimibe.Synergistic effect of simvastatin and ezetimibe on lipid and pro-inflammatory profiles in pre-diabetic subjectsNPC1L1 and cholesterol transportEzetimibe: a novel cholesterol-lowering agent that highlights novel physiologic pathways.Ezetimibe/simvastatin vs simvastatin in coronary heart disease patients with or without diabetes.Dyslipidemia in HIV-positive patients: a randomized, controlled, prospective study on ezetimibe+fenofibrate versus pravastatin monotherapy.Impact of circulating cholesterol levels on growth and intratumoral androgen concentration of prostate tumorsEfficacy, safety and tolerability of ongoing statin plus ezetimibe versus doubling the ongoing statin dose in hypercholesterolemic Taiwanese patients: an open-label, randomized clinical trialLDLR-Gene therapy for familial hypercholesterolaemia: problems, progress, and perspectivesEzetimibe reduces plant sterol accumulation and favorably increases platelet count in sitosterolemia.Effects of ezetimibe added to ongoing statin therapy on C-reactive protein levels in hypercholesterolemic patients.Ezetimibe restores biliary cholesterol excretion in mice expressing Niemann-Pick C1-Like 1 only in liverEffectiveness of Ezetimibe in Reducing the Estimated Risk for Fatal Cardiovascular Events in Hypercholesterolaemic Patients with Inadequate Lipid Control While on Statin Monotherapy as Measured by the SCORE Model.Ezetimibe: a selective cholesterol absorption inhibitor.A randomized, double-blind, placebo-controlled study of the effect of ezetimibe on glucose metabolism in subjects with type 2 diabetes mellitus and hypercholesterolemia.High-density lipoprotein (HDL) cholesterol: leveraging practice-based biobank cohorts to characterize clinical and genetic predictors of treatment outcome.Pharmacologic strategies for the prevention of atherosclerotic plaque progression.Simvastatin plus ezetimibe: combination therapy for the management of dyslipidaemia.Physiological role of hepatic NPC1L1 in human cholesterol and lipoprotein metabolism: new perspectives and open questions.Modulation of lipid metabolism with the overexpression of NPC1L1 in mouse liver.Model-based development of gemcabene, a new lipid-altering agent.Combination therapy with ezetimibe and simvastatin to achieve aggressive LDL reduction.Combination of statin and ezetimibe for the treatment of dyslipidemias and the prevention of coronary artery disease.Cholesterol absorption inhibitors as a therapeutic option for hypercholesterolaemia.Elimination of endoplasmic reticulum stress and cardiovascular, type 2 diabetic, and other metabolic diseases.Non-low-density lipoprotein cholesterol-associated actions of ezetimibe: an overview.Ezetimibe's effect on platelet aggregation and LDL tendency to peroxidation in hypercholesterolaemia as monotherapy or in addition to simvastatin.Functional characterization of genetic variants in NPC1L1 supports the sequencing extremes strategy to identify complex trait genes.Ezetimibe: an update on the mechanism of action, pharmacokinetics and recent clinical trials.Extracellular loop C of NPC1L1 is important for binding to ezetimibe
P2860
Q24658031-CA430D64-5CAD-4F1D-BD74-5D2C923239DCQ24812046-64D11A73-271B-4FEE-A374-83870222CC75Q26798119-B19DF6E5-046C-4104-A731-C0850E03F966Q26828489-2D510FA7-6191-46D2-B2E2-50A5CA1848EDQ28220294-86FED687-0ED1-495F-9473-F35ECEEDC232Q28573173-8B1B6A1C-567F-48A8-9947-A233D683E9CEQ33577611-DF9C7EE1-87D6-412C-B6FE-3A0E79EFDE10Q33668002-6C8A2D0D-9A10-4154-BE4A-FF3E26CF516AQ33732687-02688C9A-DA87-4E1D-96DA-38D05A7050A6Q33826605-07173274-62BF-4DBB-AC6F-3B340B5E3A47Q33984025-23B3BD5D-6341-4796-9D50-23B2D6D7C2B9Q33986458-E6BE6C1E-639B-4BBA-A060-4AEBD6193DA1Q34019608-D4FEA520-446E-4315-9EBF-F9988F7EE7F8Q34049540-34BE6D8D-0083-4002-8F6B-E7AF60521C6FQ34053876-1656CCF5-0CE2-4F22-9064-80FE3351D553Q34079102-0FEB12DB-4707-4853-B5C2-CB96C4BF33AFQ34141720-F1C8C815-79A6-41C5-BFCE-1658BB2B29DAQ34279028-06799A5D-C3C9-438D-9794-8873E652029CQ34467839-01D95B74-9770-459D-AC79-AA92C1BB2EEAQ34758494-5AEF42CC-D587-4600-ABC0-0A4078637D2DQ35048374-6D7086F5-A0D0-483A-B0F1-B2B03CF3F924Q35119043-9606AC22-B9EC-4CAD-8305-A84EDC4AD4C3Q35203211-27858E69-AB50-4E16-8C40-E3A0123E8EB8Q35585225-53F5A60F-B095-429C-8130-3CD2068AB23CQ35669490-0E28A942-8D16-4663-86CE-A26F5C601A0CQ35844499-88526354-08AE-45AB-A7FD-3B8CC7F31004Q35925692-C4C29649-7B4F-4195-B021-35B9BCD7A4F3Q36040720-7DADC2E6-52ED-4ECD-8CB2-3EED5E1D530DQ36302700-4EEF56B7-E0FC-4578-9843-D87B14FED144Q36302709-A9D460F4-019A-4431-859C-9688BDE35F0AQ36341650-2A3644C7-A625-41F8-8045-F0C9CA0AFBC8Q36569771-7F78BDEC-6DD4-4656-9791-8E65B403A122Q36587621-A4B03902-2FF7-4BED-A00F-7188870A09C3Q36623056-65DB93CA-A55E-485F-BB87-78F64CD258FCQ36634922-8025184D-0F3F-4957-823F-921D19380871Q36653658-921D12A6-E1C3-43A1-AE33-BE6F33173660Q36729113-FDBE03D4-7405-4840-8365-11692B0DDE5CQ36739988-6C84D0CE-35BD-48E3-BAAB-0FE44551D22EQ36835839-F64F2DF0-0867-4961-8FF8-27FD611A62E3Q36837498-BEBB39ED-E81B-4CD6-883F-0B29D7BC48EA
P2860
Effects of ezetimibe, a new cholesterol absorption inhibitor, on plasma lipids in patients with primary hypercholesterolemia.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
2003年论文
@zh
2003年论文
@zh-cn
name
Effects of ezetimibe, a new ch ...... primary hypercholesterolemia.
@en
type
label
Effects of ezetimibe, a new ch ...... primary hypercholesterolemia.
@en
prefLabel
Effects of ezetimibe, a new ch ...... primary hypercholesterolemia.
@en
P2093
P1476
Effects of ezetimibe, a new ch ...... primary hypercholesterolemia.
@en
P2093
A P LeBeaut
C V Manion
E P Veltri
Ezetimibe Study Group
P304
P356
10.1016/S0195-668X(02)00807-2
P577
2003-04-01T00:00:00Z